2015
Tu1044 Sofosbuvir-Based Interferon-Free Regimens for Hepatitis C Infection in Patients With Compensated and Decompensated Cirrhosis: Interim Analysis of a Prospective Observational Cohort
Do A, Lim J, Liapakis A, Babas G, Caldwell C, Fortune B, Emre S, Kulkarni S, Lempit S, Mistry P, Mulligan D, Rodriguez-Davalos M, Schilsky M, Tichy E, Yoo P, Jakab S. Tu1044 Sofosbuvir-Based Interferon-Free Regimens for Hepatitis C Infection in Patients With Compensated and Decompensated Cirrhosis: Interim Analysis of a Prospective Observational Cohort. Gastroenterology 2015, 148: s-1094-s-1095. DOI: 10.1016/s0016-5085(15)33733-1.Peer-Reviewed Original Research
2005
Hepatic B‐cell non‐Hodgkin's lymphoma of MALT type in the liver explant of a patient with chronic hepatitis C infection
Orrego M, Guo L, Reeder C, De Petris G, Balan V, Douglas DD, Byrne T, Harrison E, Mulligan D, Rodriguez‐Luna H, Moss A, Reddy K, Rakela J, Vargas HE. Hepatic B‐cell non‐Hodgkin's lymphoma of MALT type in the liver explant of a patient with chronic hepatitis C infection. Liver Transplantation 2005, 11: 796-799. PMID: 15973702, DOI: 10.1002/lt.20384.Peer-Reviewed Original ResearchConceptsLiver transplantationHodgkin's lymphomaB cellsChronic hepatitis C infectionHepatitis C virus infectionHepatic B cellsC virus infectionHepatitis C infectionMarginal zone lymphomaC infectionCirrhotic patientsVirus infectionB-NHLLiver explantsMALT typeLymphomaClinical settingCommon typePatientsInfectionComplicationsTransplantation
2004
Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1
Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD, Balan V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1. Transplantation 2004, 77: 190-194. PMID: 14742979, DOI: 10.1097/01.tp.0000100481.14514.bb.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsDrug Therapy, CombinationFemaleHepacivirusHepatitis CHumansImmunosuppressive AgentsInterferon alpha-2Interferon-alphaLiver Function TestsLiver TransplantationMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRecurrenceReverse Transcriptase Polymerase Chain ReactionRibavirinRNA, ViralTime FactorsTreatment OutcomeConceptsOrthotopic liver transplantationEnd of treatmentHCV recurrenceLiver transplantationPEG-IFNHepatitis C virus recurrenceRecurrent hepatitis C infectionDiscontinuation of therapyNecro-inflammatory scoreUndetectable viral loadHepatitis C infectionResponse 6 monthsBone marrow toxicityReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionHistologic benefitRecurrent HCVVirologic clearanceC infectionVirologic responseVirus recurrenceAggressive managementCombination regimenViral clearanceViral response
2001
Increased prevelance of osteoporosis in patients with end-stage liver diseasse secondary to hepatitis C infection and alcohol
Yosfi M, Douglas D, Rakela J, Savage W, Mulligan D, Harrison M, Vargas H, Eberhard K, Moss A, Balan V. Increased prevelance of osteoporosis in patients with end-stage liver diseasse secondary to hepatitis C infection and alcohol. Gastroenterology 2001, 120: a378. DOI: 10.1016/s0016-5085(08)81877-x.Peer-Reviewed Original ResearchIncreased prevelance of osteoporosis in patients with end-stage liver diseasse secondary to hepatitis C infection and alcohol
YOSFI M, DOUGLAS D, RAKELA J, SAVAGEIII W, MULLIGAN D, HARRISON M, VARGAS H, EBERHARD K, MOSS A, BALAN V. Increased prevelance of osteoporosis in patients with end-stage liver diseasse secondary to hepatitis C infection and alcohol. Gastroenterology 2001, 120: a378-a378. DOI: 10.1016/s0016-5085(01)81877-1.Peer-Reviewed Original Research